Draeger warned that if a cracked hose is used, the hose may fall off or leak, resulting in restricted ventilation or delayed therapy which could lead to desaturation, hypoxia, or patient death. ^[1] The U.S. Food and Drug Administration (FDA) issued an Early Alert to notify the public of a potentially high-risk device issue involving the Draeger VentStar Resus Neo. ^[2] The US Department of Defense issued new clinical guidelines establishing mandatory testosterone deficiency reviews for all active and reserve military personnel starting at age 30. ^[3] UBS initiated coverage of Getinge with a Neutral rating and a price target of 255 Swedish crowns, stating that the medical equipment maker's shares are priced as if quality issues are fully resolved. ^[4] Draeger sent a letter to affected customers on September 1 recommending that VentStar Resus Neo hoses be removed from where they are used or sold. ^[5] Draeger stated that users have detected cases of obvious cracks in the hose of the VentStar Resus Neo prior to use. ^[6] Defense Secretary Pete Hegseth announced the initiative in July, stating that caring for health involves ensuring personnel remain strong, resilient, and capable for their next deployment and for the rest of their lives. ^[7] Men aged 30 and older must undergo periodic blood tests to measure testosterone levels, while men under 30 will only be tested if they request it or if medical personnel detect alert symptoms. ^[8] The Pentagon stated that the new measure, which takes effect immediately, aims to evaluate hormonal levels to optimize the operational performance and readiness of the armed forces. ^[9] Even if Getinge cuts extraordinary quality costs to about 400 million crowns by 2029 or 2030, those costs would still equal 8%-9% of forecast free cash flow, according to UBS. ^[10] UBS classified Getinge's portfolio into three buckets - Growth Accelerators, Steady Compounders, and Growth Detractors - with Growth Accelerators expected to rise from under 30% of sales in 2025 to almost 35% by 2030. ^[11] UBS forecasts Getinge to deliver a 5% revenue and 12% earnings-per-share compound annual growth rate for 2026-2030, driven by a portfolio mix shift toward higher-growth product categories. ^[12]